A battle between the Arkansas Insurance Department and pharmaceutical manufacturers is heating up with the announcement of a hearing this summer to consider administrative penalties against AstraZeneca Pharmaceuticals LP, the drug manufacturing giant that filed a lawsuit against the state earlier this year over Act 1103 of 2021 -- the 340B Drug Pricing Nondiscrimination Act.

Related Keywords

West Virginia , United States , Mississippi , Louisiana , Springdale , Arkansas , Alan Mcclain , America Ph , Judd Semingson , Billy Roy Wilson , Merck Co , Merck Co Incyte , Jazz Pharmaceuticals Incyte , Health Resources Services Administration , B Drug Program Nondiscrimination Requirements , Arkansas Insurance Department , B Drug Pricing Program , Union Chimique Belge , Circuit Court , Community Clinic , Pfizer , Public Health Service , Astrazeneca , National Association Of Community Health Centers , Johnson , Astrazeneca Pharmaceuticals , Exelixis Pharmaceuticals , Us Supreme Court , Drug Pricing Nondiscrimination , Drug Program Nondiscrimination , Francis House , Northwest Arkansas , Booth Rand , Arkansas Insurance , Health Resources , Services Administration , Arkansas Code Annotated , Drug Pricing Program , Arkansas General Assembly , Drug Pricing Nondiscrimination Act , Pharmaceutical Research , Judge Billy Roy Wilson , Arkansas Insurance Commissioner Alan Mcclain , Jazz Pharmaceuticals , Incyte Pharmaceuticals , United Therapeutics , National Association , Community Health Centers ,